Corvus Pharmaceuticals, Inc.
CRVSHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframeCorvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation. The company carries a $1.04B market cap, placing it firmly in the small-cap category. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases.
Market Cap
$1.04B
Beta
0.94
P/E (TTM)
—
P/E (Fwd)
-13.11
EPS (TTM)
$-0.55
EPS (Fwd)
$-0.95
ROE
-30.5%
ROA
-19.2%
Cash
$236.7M
Total Debt
$834,000
Free CF
-$22.6M
52W Change
207.9%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $236.7M in cash comfortably exceeding the $834K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$22.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -30.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CRVS.